New animal models can revolutionize the study of cancer

October 9, 2012
Animal facilites of the IDIBELL

Some animal models developed by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Catalan Institute of Oncology (ICO) has served to validate the effectiveness of a new drug against ovarian cancer resistant to cisplatin. The multidisciplinary work, done in collaboration with the biopharmaceutical company Pharmamar, was published in the journal Clinical Cancer Research.

The human tumor tissue is implanted in the same nude mouse organ from which it came. This type of implant, called orthotopic, can reproduce the histological, genetic and epigenetic human tumors and the patterns of tumor spread, which is not achieved with other methods of implementation. Furthermore, these tumor models will be keys to the development of the so-called personalized medicine against various cancers. Besides ovarian tumors, researchers are experienced in orthotopic implantation of other tumors such as colon, pancreas, breast, endometrial or testicle, and and neurofibromatosis. Researchers are currently developing models of lung, head and neck tumors.

The technique has shown the effectiveness of lurbinectedin (PM01183), a drug recently approved by the (FDA) as "orphan drug" against ovarian cancer. This disease is the fifth leading cause of death among women. The survival rate is very low because it is often diagnosed at an advanced stage and appear resistances to chemotherapy with cisplatin. So, it is necessary to find alternative treatments.

The lurbinectedin is a marine-derived drug developed by the pharmaceutical company Pharmamar, from the Zeltia group, which has been shown effective against resistant to cisplatin in several studies. One of the most compelling studies in preclinical level is the work published now in . The article confirms that orthotopic implants in are useful not only to deepen the knowledge of tumors, but also to collaborate with the pharmaceutical industry in the process of developing new drugs to treat cancer. Lurbinectedin has recently demonstrated its efficacy in a Phase II study in treatment-resistant ovarian cancer.

The coordinator of the study and researcher at the IDIBELL and ICO, Alberto Villanueva, highlights the importance of the models developed in his laboratory that "allow obtaining tumors grown in mice that reproduce the immunohistochemical, genetic and epigenetic properties of the human tumors and its response to chemotherapy with cisplatin, that is the base of the treatment against ovarian cancer."

Explore further: Researchers investigate drug resistant ovarian cancer to improve clinical treatment

More information: Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer. Vidal A, Munoz C, Guillen MJ, Moreto J, Sara P, Martinez-Iniesta M, Figueras A, Padulles L, Garcia-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Marti L, Ponce J, Mollevi DG, Capella G, Condom E, Vinals F, Huertas D, Cuevas C, Esteller M, Aviles P, Villanueva A. Clin Cancer Res. 2012 Aug 15. [Epub ahead of print]

Related Stories

Researchers investigate drug resistant ovarian cancer to improve clinical treatment

August 9, 2012
(Medical Xpress) -- A new study by TCD researchers investigates drug-resistant ovarian cancer cells. The findings which have been recently published in the international publication, PLoS One will increase understanding of ...

Researchers find drug duo kills chemotherapy-resistant ovarian cancer cells

December 7, 2011
The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida. ...

Curcumin compound improves effectiveness of head and neck cancer treatment

May 19, 2011
A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived ...

'DIMming' cancer growth -- STAT: Diindolylmethane suppresses ovarian cancer

January 26, 2012
Ovarian cancer is a major cause of death worldwide. Approximately 25,000 women will be diagnosed with ovarian cancer this year and 15,000 women will die from it in the United States alone. The novel anti-cancer drug diindolylmethane ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.